Clinical outcomes of CDK4/6 inhibitors in patients with bone only metastatic breast cancer

被引：1
|
作者：
Mardani, Mahta
Noordeen, Suleyman
Clifton, Katherine
Ma, Cynthia
Luo, Jingqin
Xi, Jing
Bagegni, Nusayba
Ademuyiwa, Foluso
Suresh, Rama
Frith, Ashley
Davis, Andrew
Bose, Ron
Peterson, Lindsay
Thomas, Shana
Tao, Yu
Kobayashi, Takayuki
Xiang, Jingyu
Xu, Yalin
Su, Xinming
Weilbaecher, Katherine
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO5-05-05
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO5-05-05
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Clinical outcomes of patients with HR+HER2-advanced breast cancer with early progression on CDK4/6 inhibitors
    Clifton, Katherine K.
    Thomas, Shana N.
    Luo, Jingqin
    Xi, Jing
    Bagegni, Nusayba A.
    Ademuyiwa, Foluso O.
    Suresh, Rama
    Frith, Ashley
    Davis, Andrew A.
    Bose, Ron
    Weilbaecher, Katherine
    Hensing, Whitney L.
    Pluard, Timothy
    Cristofanilli, Massimo
    Han, Hyo S.
    Brufsky, Adam M.
    Kalinsky, Kevin
    Goel, Shom
    Wander, Seth A.
    Peterson, Lindsay L.
    Ma, Cynthia
    CANCER RESEARCH, 2023, 83 (05)
  • [42] A new perspective on the proper timing of radiotherapy during CDK4/6 inhibitor therapy in patients with "bone-only" metastatic breast cancer
    Tornyi, Ilona
    Arkosy, Peter
    Horvath, Ildiko
    Furka, Andrea
    PATHOLOGY & ONCOLOGY RESEARCH, 2023, 29
  • [43] The analysis of prescribing CDK4/6 inhibitors for patients with breast cancer in real clinical practice.
    Orlova, Rashida
    Avramenko, Inna
    Androsova, Alexandra
    Topuzov, Eldar
    Belyak, Natalia P.
    Kutukova, Svetlana
    Vakhitova, Almira
    Gluzman, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [44] CDK4/6 inhibitors in metastatic breast cancer: An Italian real-world experience
    Pantano, F.
    Scafetta, R.
    Curigliano, G.
    Criscitiello, C.
    Botticelli, A.
    Caputo, R.
    D'Auria, G.
    Garrone, O.
    Gori, S.
    Meattini, I.
    Minelli, M.
    Piras, M.
    Rossi, L.
    Stucci, L. S.
    Tagliaferri, B.
    Toss, A.
    Vernieri, C.
    Vici, P.
    Tonini, G.
    Santini, D.
    ANNALS OF ONCOLOGY, 2023, 34 : S346 - S347
  • [45] Clinical and dosimetric aspects in concurrent radiotherapy with CDK4/6 inhibitors in breast cancer
    Rebegea, Laura Florentina
    Ilie, Ana Maria
    Anghel, Rodica
    Lungu, Mihaela
    Dumitru, Mihaela Emilia
    RADIOTHERAPY AND ONCOLOGY, 2024, 194 : S632 - S633
  • [46] Assessment of Resistance Mechanisms and Clinical Implications in Patients with KRAS Mutated-Metastatic Breast Cancer and Resistance to CDK4/6 Inhibitors
    Raimondi, Lucrezia
    Raimondi, Filippo Maria
    Pietranera, Marta
    Di Rocco, Arianna
    Di Benedetto, Laura
    Miele, Evelina
    Lazzeroni, Rachele
    Cimino, Giuseppe
    Spinelli, Gian Paolo
    CANCERS, 2021, 13 (08)
  • [47] Clinical considerations of CDK4/6 inhibitors in triple-negative breast cancer
    Wang, Runtian
    Xu, Kun
    Gao, Fangyan
    Huang, Jinyi
    Guan, Xiaoxiang
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2021, 1876 (02):
  • [48] CDK4/6 inhibitors in breast cancer - from in vitro models to clinical trials
    Saleh, Lubaid
    Wilson, Caroline
    Holen, Ingunn
    ACTA ONCOLOGICA, 2020, 59 (02) : 219 - 232
  • [49] Social determinants of health and CDK4/6 inhibitor use and outcomes among patients with metastatic breast cancer
    Sathe, Claire
    Accordino, Melissa K. K.
    DeStephano, David
    Shah, Mansi
    Wright, Jason D. D.
    Hershman, Dawn L. L.
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 200 (01) : 85 - 92
  • [50] Social determinants of health and CDK4/6 inhibitor use and outcomes among patients with metastatic breast cancer
    Claire Sathe
    Melissa K. Accordino
    David DeStephano
    Mansi Shah
    Jason D. Wright
    Dawn L. Hershman
    Breast Cancer Research and Treatment, 2023, 200 : 85 - 92
12345